slot game win

slot game win Inside the failed partnership between the Giants and Daniel Jones, plus what's next for both parties - CBS Sports

Central Division opponents meet when Predators host the JetsAtria Investments Inc Reduces Holdings in National Storage Affiliates Trust (NYSE:NSA)

Singapore-based startup Biorithm has developed a monitoring device that women can use to monitor their pregnancies at home. The device, Femom, sends information on the mother and baby's heart rate to clinicians via an app. Almost 800 women a day died from "preventable causes" in pregnancy or childbirth in 2020, an "unacceptably high" figure, the World Health Organization says. 24/7 San Diego news stream: Watch NBC 7 free wherever you are More than 2 million babies died in the first 20 days of their lives in 2022, equating to around 6,500 deaths a day, according to the World Health Organization . On top of that, almost 800 women a day died from "preventable causes" in pregnancy or childbirth in 2020, an "unacceptably high" figure, the WHO says . A Singapore-based startup, Biorithm, hopes to help solve the problem with a device that women can use at home to monitor their pregnancy, while a connected mobile app transmits information such as the baby's heart rate directly to clinicians for review. "Women's health [care] has been geared towards treating women who are sick and not keeping women well," said Amrish Nair, Biorithm's chief technology officer and co-founder. "We're trying to provide technology that puts power back into women's hands ... It's no longer in hospital, but now empowering women to be able to receive care in the place of their choosing," he said, speaking to CNBC's " CNBC Tech: The Edge. " Money Report Adani Group's troubles keep growing as financial and legal headwinds get stronger Walmart pulls back on DEI efforts, removes some LBGTQ merchandise from website Biorithm's device, Femom, monitors both the maternal and fetal heart rate, and is designed to be simple to use, with the woman's navel used as a guide for accurate placement. It can be used during contractions, providing information to clinicians for interventions where necessary. Monitoring takes about 20 to 30 minutes, according to Sihem Tedjar, Biorithm's product development lead. "It's very easy to use for a non trained person or a non-health care professional, and that's where the usability and all the design work reside," Tedjar said. Femom's five electrodes capture electrical signals at the surface of the abdomen and transmit information to a dashboard, accessible by medical staff. "This device answer[s] a very basic question of all parents: how well is my baby?" said Dr Thiam Chye Tan, a startup mentor at Biorithm. Nair said in an online release that there has been a "collapse of maternal care" due to socio-economic factors and a lack of monitoring technology. Almost 95% of maternal deaths occurred in lower- and middle-income countries in 2020, according to the WHO , and in 2016 it tried to improve antenatal care and reduce the risk of pregnancy complications by issuing guidance to increase the number of contacts a pregnant woman has with health-care providers from four to eight. The global market for medical devices is projected to grow from $542 billion in 2024 to $887 billion by 2032, according to Fortune Business Insights . Biorithm was spun off from Nanyang Technological University in Singapore and Femom is in development, being used in clinical research settings. The Singapore government is investing heavily in its health sector and in 2023, Biorithm raised $3.5 million in Series A funding from government agency Enterprise Singapore and Adaptive Capital Partners. The funding is being used for the development of Femom and for the company's expansion in the U.S. and Southeast Asia. "Women's health has always faced a very tricky funding situation. It's never been the hottest topic in medical technology," Nair told CNBC. "From very early on, we got funds who have invested in us, and now funds who are led by women who have invested in us," he said. "We see the evolution of the funding landscape, and it's really been encouraging for women's health. Although a lot more needs to be done, it's certainly a start," Nair said. Also on CNBC Meet the Singapore-based tech startup aiming to democratize pregnancy care This Singaporean AI startup is disrupting a 100-year-old industry How AI is helping brands identify consumer trends fasterThe Washington Spirit face the Orlando Pride in the NWSL Final on Saturday, Nov. 23, 2024 (11/23/24) at CPKC Stadium in Kansas City, Missouri. HOW TO WATCH: Fans can watch via a free trial to DirecTVStream o r via a subscription to Paramount+ . Here’s what you need to know: What: NWSL Final Who: Washington Spirit vs. Orlando Pride When: Saturday, Nov. 23, 2024 Time : 8 p.m. ET Where: CPKC Stadium TV: CBS Live stream: DirecTVStream Here’s a recent AP story on NWSL: With technical prowess and considerable style, Marta danced around two sliding defenders, outwitted a goalkeeper and calmly scored as another player rushed forward in desperation to stop her. It was more Marta Magic. That goal last weekend helped propel the Orlando Pride into Saturday’s National Women’s Soccer League championship game against the Washington Spirit. Barbra Banda also scored in the Pride’s 3-2 semifinal victory over the Kansas City Current . While Banda has had an incredible first season with the Pride, captain Marta has been the talisman that has helped lead the team in its remarkable turnaround this year. The last time the Pride were in the NWSL playoffs was in 2017 — Marta’s first year with the club. But this season they nearly went undefeated, going 23 games without a loss to start the season before losing 2-0 to the Portland Thorns with just two regular-season games left. “I think because of the way that we did it, during this season, from beginning to now, it’s something very special that I’ve never had before with any other club that I’ve played for,” Marta said. ”Plus year by year, we see in America, strong competition. This is the best league in the world. And you never know what’s going to happen, and it’s hard to keep winning the games, being in the first place almost like the whole season. That’s why it’s really different and so special.” Marta’s goal was the latest gasp-inducing moment in a stellar career filled with them. Known by just her first name, the 38-year-old is a six-time FIFA world player of the year. “Let’s see if tomorrow I can do something similar — or even better,” Marta said on Friday. Her teammate Kylie Strom chimed in: “That was the greatest goal I’ve ever witnessed, hands down.” Appropriate. Earlier this year, FIFA announced that the best goal in women’s soccer each year would earn the Marta Award. In a lighthearted moment the day before the title match, Marta was asked if she thought it was possible she might give the award to herself. “You guys need to decide, because who votes for the best goal in the year? It’s you. It’s the people in the public. So it should be really interesting, like Marta’s Award goes to Marta!” she said with a laugh. Marta has played in six World Cups for Brazil and played this summer in her sixth Olympics, winning a silver medal after falling in the final to the United States . She previously said this would be her final year with the national team. But since then Brazil was named the host of the 2027 Women’s World Cup. “I had a conversation with my coach, the national team coach, and I was really clear about playing in 2027. I told him it’s not my goal anymore,” she said. “But I’m always available to help the national team. And if they think I still can do something during this preparation for the World Cup, yeah, I would be happy to help them.” Marta’s club career started in Brazil when she was just 16. She has also played in Sweden and in the U.S. professional women’s leagues that came before the NWSL. With nine regular-season goals, Marta has had one of her best seasons since she joined the Pride. “I can never pick a side, I never pick favorites — but I love to see this for Marta," U.S. coach Emma Hayes said. “Marta is someone we all like, admire and are grateful for. And that goal was just like prime Marta at her best. And so grateful for and thankful for her that she got the opportunity with another game with her team.” The Pride went 18-2-6 this season, clinching the NWSL Shield for the first trophy in club history. Orlando also set a record with 60 regular-season points to finish atop the standings. “We are sitting top of the table, but I think there still are a lot of doubters. I think there’s people out there who say, maybe this was a one-off season,” Strom said. “But we’re here to prove them all wrong. So I think we do carry a bit of that underdog mentality still with us.” The second-seeded Spirit advanced to the title match at Kansas City’s CPKC Stadium last weekend on a penalty shootout after a 1-1 draw against defending champions Gotham FC. RECOMMENDED • nj .com Michigan vs. Northwestern FREE LIVE STREAM (11/23/24) | How to watch, time, TV channel for college football Nov. 23, 2024, 1:30 p.m. Saint Louis vs. Wichita State FREE LIVE STREAM (11/22/24): Watch men’s college basketball online | Time, TV, Nov. 22, 2024, 8:30 p.m. The Spirit’s roster includes Trinity Rodman, a standout forward who formed the so-called “Triple Espresso” trio with Mallory Swanson and Sophia Smith for the United States at the Olympics. Thank you for relying on us to provide the journalism you can trust. Cayden Steele may be reached at CSteele@njadvancemedia.com

Tens of thousands of Spaniards protest housing crunch and high rents in BarcelonaDelivering Optimized, Outbound-Focused Contact Center Solutions for Modern Businesses LAUDERDALE LAKES, Fla. , Dec. 27, 2024 /PRNewswire/ -- outboundIQ www.outboundiq.com proudly announces its accreditation as a Five9 Certified Implementation Partner (CIP), a distinction that reflects its deep expertise in optimizing and streamlining outbound-focused contact center operations. With a team of seasoned Five9 veterans, expert programmers, and industry thought leaders, outboundIQ is uniquely equipped to help businesses of all sizes unlock the full potential of Five9's Virtual Contact Center platform. Optimized Solutions for Complex Contact Center Needs outboundIQ specializes in providing expedited, outbound-focused contact center implementations, integrating advanced features such as inbound and outbound Voice, SMS, Chat, Email, Salesforce Integration, and other third-party app integrations. Clients can also leverage ongoing optimization engagements and monthly retainers for strategic consulting designed to support long-term, outreach-focused success. "Who better to handle your domain configuration than the experts that understand the outbound contact center world. To be an outbound expert, you must know 3 things; how to configure the domain front end, how the architecture interprets that design, and how carriers respond to your dialing behavior as a result of the build. outboundIQ has the advantage of deeply understanding all 3 things. Our experts are seasoned professionals that will guide toward the best build for your business. You tell us about your business, your needs and your processes, and we will build you a domain fit for purpose. outboundIQ offers best in class Domain Optimization, Implementation and Consulting for customers of all sizes and complexity. Due to our methodology and proprietary automations, we are able to bring our customers' projects to life within accelerated timeframes." - Jessica Clay , VP Support and Services "We launched our business in June and were fortunate to connect with the incredible team at outboundIQ early on. Navigating the world of outbound calling and building efficient prospecting systems isn't easy, but the entire team at outboundIQ brought our vision to life seamlessly. They implemented our ideas quickly and executed them flawlessly. Since partnering with them, our contact rates have significantly improved, our conversions have increased, and our overall business is thriving. We're deeply grateful for this collaboration and look forward to continuing our work together on future endeavors!" - Tim, Lit Financial "I genuinely don't know enough ways to thank the entire outboundIQ team. I inherited a domain riddled with mistakes, tangled beyond belief, and I had essentially planned to scrap the whole thing and start over. That's when this team, led by Jessica Clay's brilliance, took over to understand exactly what I wanted to create and completely revitalized my domain. We are all beyond thankful as they continue to consult for us to this day and I see no reason to stop. Thank you, Jessica, Jason, Rudy, Bruno, Sandy and everyone who gets the pleasure of working with these domain geniuses!" - Michael, Lifetime Home Remodeling A Holistic Approach to Outbound Excellence Creating a competitive, consumer-focused outreach program requires more than just advanced technology. As outboundIQ explains, a thriving contact center functions like a high-performing racing team: The Car: Five9 Virtual Contact Center provides a cutting-edge technology foundation. The Driver: Strong Dialer Administrators who skillfully manage operations. The Pit Crew: IT/Support teams ensuring seamless functionality. The Spotters: Data Analytics and Reporting experts optimizing performance. The Fuel: High-quality data driving better outcomes. outboundIQ's professional services team brings these critical elements together, ensuring clients achieve best-in-class outbound operations that prioritize consumer experience while maintaining a competitive edge. A Call to Collaboration With its new CIP certification, outboundIQ invites businesses to explore select partnership opportunities and projects to reimagine their contact center operations. Whether through expedited implementations or ongoing strategic consulting, outboundIQ is committed to driving measurable results for its clients. About outboundIQ outboundIQ delivers optimized, outbound-focused contact center implementations, combining years of Five9 expertise with cutting-edge strategies to help businesses achieve exceptional outreach outcomes. As a Five9 Certified Implementation Partner, outboundIQ provides tailored solutions to meet the unique needs of modern organizations. About Five9 Five9 is a digital enterprise's leading cloud contact center and software provider. The Five9 Intelligent CX Platform is reliable, secure, compliant, and scalable, designed to create exceptional personalized customer experiences. www.five9.com Media contact: Sandy Tafur Phone: 404-660-5314 mail: sandy@outboundiq.com View original content to download multimedia: https://www.prnewswire.com/news-releases/outboundiq-achieves-certified-implementation-partner-cip-status-with-five9-302339797.html SOURCE outboundIQ

Have you heard that a recent study found a strong connection between volunteering and more positive emotions, less loneliness, and more social support? And, says Dr. Eric S. Kim at the University of British Columbia, “These things have downstream effects, such as increased healthy behaviors, as well as increased healthier biological function such as reduced inflammation.” Benefits we all can use, right? Especially now. In the wake of this month’s election, many among us who care deeply about the environment and our wild lands could use some positive emotions. With the news full of the incoming administration’s plans to open public lands to more energy development and logging, gut regulatory agencies like the EPA, stop efforts to slow climate change and even transfer national lands to states or private developers, it’s enough to bring out the Grinch in some of us. But, rather than hunkering down and fretting over the fate of the planet, it’s time to volunteer. The good news is that there are nonprofit groups in Summit County that need your volunteer efforts to help protect our local public lands. And this is the time of year when planning and advocacy work gets done so that we are ready to head out on the trails from May through October. Local groups like Eagle Summit Wilderness Alliance and Friends of the Dillon Ranger District (welcome volunteers. For example, the all-volunteer Eagle Summit Wilderness Alliance works with the U.S. Forest Service to protect the four congressionally-designated Wilderness Areas in Eagle and Summit Counties — the Eagles Nest, Flat Tops, Holy Cross and Ptarmigan Peak Wildernesses. After all, most of our favorite trails lead into wilderness. Sixty years ago this year, the 1964 Wilderness Act was signed into law, recognizing that with our “increasing population, accompanied by expanding settlement and growing mechanization,” some lands needed to be preserved “in their natural condition” to “secure for present and future generations the benefits of wilderness.” The act recognized the value of preserving “an area where the earth and its community of life are untrammeled by man, where man himself is a visitor who does not remain.” Being so easily accessible from major population centers and attracting millions of visitors each year, our wilderness areas need you. Many visitors are unaware that when they pass the wilderness sign, they’ve entered an area requiring special protection, including compliance with regulations to keep these precious lands pristine. That’s where volunteers, both on the trails or at trailheads, help educate trail users about our unique wilderness areas. And since mechanized and wheeled equipment aren’t allowed in wilderness, volunteers are essential for trail maintenance. Upcoming Forest Service hiring freezes make the need for volunteers even greater. Eagle Summit Wilderness Alliance says participants volunteer for seven different reasons: So, do something nice for yourself and our natural world — volunteer for public lands.CRANFORD, N.J. , Dec. 27, 2024 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies, today reported business and financial results for the fiscal full year ended September 30, 2024 . Fiscal Full Year 2024 Business Highlights and Subsequent Developments Financial Highlights "Reflecting on 2024, Citius Oncology has achieved pivotal milestones that underscore our commitment to advancing cancer therapeutics," stated Leonard Mazur , Chairman and CEO of Citius Oncology. "The FDA's approval of LYMPHIR for the treatment of cutaneous T-cell lymphoma marks a significant advancement in providing new options for patients battling this challenging disease. It is the only targeted systemic therapy approved for CTCL patients since 2018 and the only therapy with a mechanism of action that targets the IL-2 receptor. Additionally, the successful merger forming Citius Oncology, now trading on Nasdaq under the ticker CTOR, strengthens our position in the oncology sector. We expect it to facilitate greater access to capital to fund LYMPHIR's launch and the Company's future growth. With a Phase I investigator-initiated clinical trial combining LYMPHIR with pembrolizumab demonstrating promising preliminary results, indicating potential for enhanced treatment efficacy in recurrent solid tumors, and preliminary results expected from a second investigator trial with CAR-T therapies in 2025, we remain excited about the potential of LYMPHIR as a combination immunotherapy." "These accomplishments reflect the dedication of our team and the trust of our investors. As we look ahead, we remain steadfast in our mission to develop innovative therapies that improve the lives of cancer patients worldwide," added Mazur. FULL YEAR 2024 FINANCIAL RESULTS: Research and Development (R&D) Expenses R&D expenses were $4.9 million for the full year ended September 30, 2024 , compared to $4.2 million for the full year ended September 30, 2023 . The increase reflects development activities completed for the resubmission of the Biologics License Application of LYMPHIR in January 2024 , which were associated with the complete response letter remediation. General and Administrative (G&A) Expenses G&A expenses were $8.1 million for the full year ended September 30, 2024 , compared to $5.9 million for the full year ended September 30, 2023 . The increase was primarily due to costs associated with pre-commercial and commercial launch activities of LYMPHIR including market research, marketing, distribution and drug product reimbursement from health plans and payers. Stock-based Compensation Expense For the full year ended September 30, 2024 , stock-based compensation expense was $7.5 million as compared to $2.0 million for the prior year. The primary reason for the $5.5 million increase was due to the amounts being realized over 12 months in the year ended September 30, 2024 , as compared to three months post-plan adoption in the year ended September 30, 2023 . Net loss Net loss was $21.1 million , or ($0.31) per share for the year ended September 30, 2024 , compared to a net loss of $12.7 million , or ($0.19) per share for the year ended September 30, 2023 . The $8.5 million increase in net loss was primarily due to the increase in our operating expenses. About Citius Oncology, Inc. Citius Oncology specialty is a biopharmaceutical company focused on developing and commercializing novel targeted oncology therapies. In August 2024 , its primary asset, LYMPHIR, was approved by the FDA for the treatment of adults with relapsed or refractory CTCL who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds $400 million , is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology's competitive positioning. Citius Oncology is a publicly traded subsidiary of Citius Pharmaceuticals. For more information, please visit www.citiusonc.com Forward-Looking Statements This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Oncology. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated, and, unless noted otherwise, that apply to Citius Oncology are: our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; our ability to commercialize LYMPHIR and any of our other product candidates that may be approved by the FDA; the estimated markets for our product candidates and the acceptance thereof by any market; the ability of our product candidates to impact the quality of life of our target patient populations; our dependence on third-party suppliers; our ability to procure cGMP commercial-scale supply; risks related to research using our assets but conducted by third parties; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; government regulation; competition; as well as other risks described in our Securities and Exchange Commission ("SEC") filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the SEC's website at www.sec.gov , including in Citius Oncology's Annual Report on Form 10-K for the year ended September 30, 2024 , filed with the SEC on December 27, 2024 , as updated by our subsequent filings with the SEC. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. Investor Contact: Ilanit Allen ir@citiuspharma.com 908-967-6677 x113 Media Contact: STiR-communications Greg Salsburg Greg@STiR-communications.com -- Financial Tables Follow – CITIUS ONCOLOGY, INC. CONSOLIDATED BALANCE SHEETS SEPTEMBER 30, 2024 AND 2023 2024 2023 Current Assets: Cash and cash equivalents $ 112 $ — Inventory 8,268,766 — Prepaid expenses 2,700,000 7,734,895 Total Current Assets 10,968,878 7,734,895 Other Assets: In-process research and development 73,400,000 40,000,000 Total Other Assets 73,400,000 40,000,000 Total Assets $ 84,368,878 $ 47,734,895 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts payable $ 3,711,622 $ 1,289,045 License payable 28,400,000 — Accrued expenses — 259,071 Due to related party 588,806 19,499,119 Total Current Liabilities 32,700,429 21,047,235 Deferred tax liability 1,728,000 1,152,000 Note payable to related party 3,800,111 — Total Liabilities 38,228,540 22,199,235 Stockholders' Equity: Preferred stock - $0.0001 par value; 10,000,000 shares authorized: no shares issued and outstanding — — Common stock - $0.0001 par value; 100,000,000; 71,552,402 and 67,500,000 shares issued and outstanding at September 30, 2024 and 2023, respectively 7,155 6,750 Additional paid-in capital 85,411,771 43,658,750 Accumulated deficit (39,278,587) (18,129,840) Total Stockholders' Equity 46,140,339 25,535,660 Total Liabilities and Stockholders' Equity $ 84,368,878 $ 47,734,895 CITIUS ONCOLOGY, INC. CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE YEARS ENDED SEPTEMBER 30, 2024 AND 2023 2024 2023 Revenues $ — $ — Operating Expenses: Research and development 4,925,001 4,240,451 General and administrative 8,148,929 5,915,290 Stock-based compensation – general and administrative 7,498,817 1,965,500 Total Operating Expenses 20,572,747 12,121,241 Loss before Income Taxes (20,572,747) (12,121,241) Income tax expense 576,000 576,000 Net Loss $ (21,148,747) $ (12,697,241) Net Loss Per Share – Basic and Diluted $ (0.31) $ (0.19) Weighted Average Common Shares Outstanding – Basic and Diluted 68,053,607 67,500,000 CITIUS ONCOLOGY, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE YEARS ENDED SEPTEMBER 30, 2024 AND 2023 2024 2023 Cash Flows From Operating Activities: Net loss $ (21,148,747) $ (12,697,241) Adjustments to reconcile net loss to net cash provided by operating activities: Stock-based compensation expense 7,498,817 1,965,500 Deferred income tax expense 576,000 576,000 Changes in operating assets and liabilities: Inventory (2,133,871) - Prepaid expenses (1,100,000) (5,044,713) Accounts payable 2,422,577 1,196,734 Accrued expenses (259,071) (801,754) Due to related party 14,270,648 14,805,474 Net Cash Provided By Operating Activities 126,353 - Cash Flows From Investing Activities: License payment (5,000,000) - Net Cash Used In Investing Activities (5,000,000) - Cash Flows From Financing Activities: Cash contributed by parent 3,827,944 - Merger, net (2,754,296) - Proceeds from issuance of note payable to related party 3,800,111 - Net Cash Provided By Financing Activities 4,873,759 - Net Change in Cash and Cash Equivalents 112 - Cash and Cash Equivalents – Beginning of Year - - Cash and Cash Equivalents – End of Year $ 112 $ - Supplemental Disclosures of Cash Flow Information and Non-cash Activities: IPR&D Milestones included in License Payable $ 28,400,000 $None

Maharashtra Assembly Election Result 2024: Baramati showdown – Ajit Pawar or nephew Yugendra?Shatel: Nebraska is going to a bowl game again — and here are some dream matchups